SMi Group announces the 10th Annual RNA Therapeutics Conference in London on February 20th - 21st 2019. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.
Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.
Join us in February 2019, for SMi鈥檚 10thannual sell out conference, RNA Therapeutics. Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.
Network and learn from key opinion leaders such as:
CHAIRS FOR 2019:
Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca
GUEST SPEAKERS:
Carsten Rudolf, Chief Executive Officer, Ethris Gmbh
Paul Agris, Founder and Director, The RNA Institute
KEYNOTE SPEAKERS:
Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.
David Giljohan, CEO, Exicure
Ingmar Hoerr, Founder & CEO, CureVac AG
David Blakey, Chief Scientific Officer, MiNA Therapeutics
Andr茅 Gerber, Professor of RNA Biology, University of Surrey
Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
Markus Mandler, Chief Scientific Officer, Accanis Biotech
Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche
Hans Kistemaker, Associate Director, ProQR
2019 FEATURED HIGHLIGHTS:
Discover the clinical progress of Spherical Nucleic Acids at Exicure
Understand Sanofi鈥檚 strategies to deliver therapeutic oligonucleotides across biobarriers
Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
Explore the development of small activating RNA 鈥� from bench to bedside with MiNA Therapeutics
Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK
Check out the brochure online: http://www.therapeutics-rna.com/rscwl
Early-Bird Rates
REGISTER BY 30TH NOVEMBER AND SAVE 拢200
REGISTER BY 15TH DECEMBER AND SAVE 拢100
Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.
Join us in February 2019, for SMi鈥檚 10thannual sell out conference, RNA Therapeutics. Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.
Network and learn from key opinion leaders such as:
CHAIRS FOR 2019:
Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca
GUEST SPEAKERS:
Carsten Rudolf, Chief Executive Officer, Ethris Gmbh
Paul Agris, Founder and Director, The RNA Institute
KEYNOTE SPEAKERS:
Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.
David Giljohan, CEO, Exicure
Ingmar Hoerr, Founder & CEO, CureVac AG
David Blakey, Chief Scientific Officer, MiNA Therapeutics
Andr茅 Gerber, Professor of RNA Biology, University of Surrey
Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
Markus Mandler, Chief Scientific Officer, Accanis Biotech
Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche
Hans Kistemaker, Associate Director, ProQR
2019 FEATURED HIGHLIGHTS:
Discover the clinical progress of Spherical Nucleic Acids at Exicure
Understand Sanofi鈥檚 strategies to deliver therapeutic oligonucleotides across biobarriers
Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
Explore the development of small activating RNA 鈥� from bench to bedside with MiNA Therapeutics
Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK
Check out the brochure online: http://www.therapeutics-rna.com/rscwl
Early-Bird Rates
REGISTER BY 30TH NOVEMBER AND SAVE 拢200
REGISTER BY 15TH DECEMBER AND SAVE 拢100
